These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 34646387)

  • 1. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
    Wang D; Veo B; Pierce A; Fosmire S; Madhavan K; Balakrishnan I; Donson A; Alimova I; Sullivan KD; Joshi M; Erlander M; Ridinger M; Foreman NK; Venkataraman S; Vibhakar R
    Neuro Oncol; 2022 Mar; 24(3):414-426. PubMed ID: 34477871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
    Hagege A; Saada-Bouzid E; Ambrosetti D; Rastoin O; Boyer J; He X; Rousset J; Montemagno C; Doyen J; Pedeutour F; Parola J; Bourget I; Luciano F; Bozec A; Cao Y; Pagès G; Dufies M
    Cell Rep Med; 2022 Sep; 3(9):100659. PubMed ID: 36130479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro.
    Wu X; Wu J
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):183-195. PubMed ID: 38536443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
    Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
    BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
    Giordano A; Liu Y; Armeson K; Park Y; Ridinger M; Erlander M; Reuben J; Britten C; Kappler C; Yeh E; Ethier S
    PLoS One; 2019; 14(11):e0224420. PubMed ID: 31751384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.
    Chiappa M; Decio A; Guarrera L; Mengoli I; Karki A; Yemane D; Ghilardi C; Scanziani E; Canesi S; Barbera MC; Craparotta I; Bolis M; Fruscio R; Grasselli C; Ceruti T; Zucchetti M; Patterson JC; Lu RA; Yaffe MB; Ridinger M; Damia G; Guffanti F
    Cell Death Dis; 2024 Jul; 15(7):521. PubMed ID: 39039067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
    Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α
    Wang X; Li B; Ciotkowska A; Rutz B; Erlander MG; Ridinger M; Wang R; Tamalunas A; Waidelich R; Stief CG; Hennenberg M
    Eur J Pharmacol; 2020 Apr; 873():172985. PubMed ID: 32017934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
    Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
    Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.
    Fu G; Somasundaram RT; Jessa F; Srivastava G; MacMillan C; Witterick I; Walfish PG; Ralhan R
    Oncotarget; 2016 Mar; 7(13):17162-81. PubMed ID: 26934445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
    Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
    Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
    Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
    Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
    Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.